trending Market Intelligence /marketintelligence/en/news-insights/trending/dJgKKYpzC0MZ4Jsco13UJQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Golden Meditech to divest its stake in China Cord Blood for 5.76B yuan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Golden Meditech to divest its stake in China Cord Blood for 5.76B yuan

Golden Meditech Holdings Ltd. is selling the entirety of its holdings in China Cord Blood Corp. to Nanjing Yingpeng Huikang Medical Industry Investment Partnership for 5.76 billion Chinese yuan in cash.

The sale of the 65.4% stake will result in a "significant return to both the group and its shareholders," Golden Meditech said in a statement. The company plans to use the funds to consolidate its healthcare services platform while engaging in a strategic diversification.

Golden Meditech is guaranteeing performance at China Cord Blood and has agreed to make compensatory payments in case of an earnings shortfall.

As of Dec. 29, US$1 was equivalent to 6.95 yuan.